School of Medicine
Showing 1-10 of 52 Results
Saul A. Rosenberg, MD, Professor of Lymphoma
Current Research and Scholarly Interests Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.
Ash A. Alizadeh, MD/PhD
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly Interests My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.
Douglas W. Blayney, MD, FACP
Professor of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Improving the quality of cancer care at Stanford, in our network of care, and nationally
Robert W. Carlson
Professor of Medicine (Oncology and General Internal Medicine/Medical Informatics) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests Clinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.
Professor of Medicine (Oncology) and of Biochemistry
Current Research and Scholarly Interests Our laboratory seeks to understand how cells repair DNA damage. We currently focus on how non-homologous end joining proteins assemble on DNA ends to juxtapose them for repair of DNA double-strand breaks.
We are collaborating in the development of a point-of-care device to measure ammonia from a drop of blood. The device will facilitate diagnosis and management of urea cycle defects, liver disease, and chemobrain due to elevated ammonia.
A. Dimitrios Colevas
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head and Neck Surgery at the Stanford University Medical Center
Current Research and Scholarly Interests Multi- modality treatment of Head and Neck Cancer
Phase 1 clinical trials
Assistant Professor of Medicine (Oncology) and of Genetics
Current Research and Scholarly Interests The Curtis laboratory is focused on the development and application of innovative experimental, computational, and analytical approaches to improve the diagnosis, treatment, and early detection of cancer.
Millie Das, MD
Clinical Assistant Professor, Medicine - Oncology
Bio Dr. Das specializes in the treatment of lung cancer. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She has a strong interest in clinical research, and in her free time, she enjoys spending time with her family, including her 2 young daughters.
Alice C. Fan
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly Interests My laboratory investigates how oncogenes initiate and sustain tumorigenesis. I have developed model systems whereby I can conditionally activate oncogenes in normal human and mouse cells in tissue culture or in specific tissues of transgenic mice. In particular using the tetracycline regulatory system, I have generated a conditional model system for MYC-induced tumors. I have shown that cancers caused by the conditional over-expression of the MYC proto-oncogene regress with its inactivation.